Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Our mission is to deliver best-in-class therapeutics to patients with debilitating eye diseases

See How

Pursuing Innovative Ocular Biotherapeutics

Ocugen, Inc. is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. The Company’s lead clinical candidate (OCU300) is currently in Phase 3 for treating ocular graft versus host disease (oGVHD) and is the first and only therapeutic with orphan drug designation for oGVHD, providing certain regulatory and economic benefits. The Company's second lead candidate for treating dry eye disease (OCU310) is also expected to enter pivotal clinical trials in 2018. Both OCU300 and OCU310 leverage Ocugen's patented OcuNanoE - Ocugen's ONE Platform™ technology to enhance the efficacy of topical ophthalmic therapeutics. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400).

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

  • OCU300
    For ocular graft versus host disease (oGVHD)
  • OCU310
    For treatment of dry eye disease (DED)
  • OCU100
    For treatment of retinis pigmentosa
  • OCU200
    For wet age-related macular degneration
  • OCU400
    For treatment of inherited retinal disorders

Addressing a common complication that occurs in about 60% of patients who have undergone allogeneic hemotological stem cell transplantation, or bone marrow transplants.

In development under the FDA’s 505(b)(2) regulatory pathway

Learn More About OCU300

Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.

In development under the FDA’s 505(b)(2) regulatory pathway

Learn More About OCU310

Addressing a group of inherited diseases that cause progressive retinal degeneration, affecting approximately 100,000 people in the US and similar number in Europe.

Learn More About OCU100

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400

Press Releases

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

OCU300
For ocular graft versus host disease (oGVHD)

Addressing a common complication that occurs in 40-60% of patients who have undergone allogenic hemotological stem cell transplantation, or bone marrow transplants.

In development under the FDA’s 505(b)(2) regulatory pathway

Learn More About OCU300
OCU310
For treatment of dry eye disease (DED)

Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.

In development under the FDA’s 505(b)(2) regulatory pathway

Learn More About OCU310
OCU100
For treatment of retinis pigmentosa

Addressing a group of inherited diseases that cause progressive retinal degeneration, affecting approximately 100,000 people in the US and similar number in Europe.

Learn More About OCU100

OCU200
For wet age-related macular degneration

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200

OCU400
For treatment of inherited retinal disorders

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400
Sign up to receive email alerts with the latest news from Ocugen Subscribe